Healthcare AI Surges as NVIDIA Data Shows 70% Adoption Rate

Technology is reshaping healthcare at an unprecedented pace, with artificial intelligence now embedded across clinical, research and operational environments. NVIDIA's latest "State of AI in Healthcare and Life Sciences" survey report indicates the industry has moved decisively beyond pilot projects into full-scale deployment, with 70% of organisations now actively using AI technologies.

The shift represents a significant acceleration in digital transformation. According to the survey of more than 600 industry professionals, AI adoption has increased from 63% in 2024, while generative AI and large language model usage has jumped from 54% to 69% over the same period.

Technology drives sector-wide transformation

Adoption patterns vary across healthcare segments, with digital healthcare leading at 78% active use, followed by pharmaceutical and biotech organisations at 74% and medical technology at 70%. Even traditionally conservative sectors are accelerating technology integration – payers and providers recorded a 13% year-on-year increase, rising from 43% to 56%.

"The most visible and scalable impact of AI will come from logistics and administrative streamlining," says John Nosta, President of NostaLab, a healthcare think tank. "That's where adoption curves are already steep, scheduling, documentation, coding, utilisation management and care coordination."

The technological infrastructure supporting this expansion reflects diverse approaches. Predictive and data analytics remain foundational, with 65% of organisations using AI for data analytics and data science and 51% leveraging predictive analytics. Clinical integration is advancing simultaneously – 42% cite clinical decision support as their top AI use case, while 38% report using AI for medical imaging and 38% for administrative workflow optimisation.

Targeted applications generate financial returns

The technology delivers the strongest returns when applied to specific, well-defined use cases. In the medical technology segment, 57% report achieving ROI from AI in medical imaging. Similarly, 46% of pharmaceutical and biotech organisations report ROI from AI in drug discovery and development.

"Scaling generative AI in healthcare starts with focusing on real clinical and operational problems, rather than the technology itself," says Dr Annabelle Painter, Clinical AI Strategy Lead at Visiba UK.

Digital healthcare organisations identify virtual health assistants and chatbots as top ROI drivers, while payers and providers emphasise administrative task automation and workflow optimisation. From a business performance perspective, the survey finds that 85% of management respondents say AI has increased annual revenue and 80% report reduced annual costs. Notably, 44% state that AI increased revenue by more than 10%, with small companies benefiting significantly – 56% report revenue growth exceeding 10%.

Agentic AI emerges as a frontier technology

A notable technological development is the emergence of agentic AI. NVIDIA's data shows that 47% of respondents say they are actively using or assessing AI agents, including 22% who have already deployed them and 19% planning deployment within the next year.

Top use cases include knowledge management and retrieval (46%), literature review and analysis (38%) and internal process optimisation (37%). In pharma and biotech, 55% use agentic AI for literature review and nearly half deploy it for drug discovery and biomarker identification.

Open-source tools are central to this technological expansion. The survey found that 82% of respondents say open-source models and software are moderately to extremely important to their AI strategy, enabling organisations to fine-tune models for specialised clinical and research tasks.

"Open models will shape the intellectual field," says John Nosta. "They are essential for exploration and for keeping the field honest. But in clinical environments where safety, liability and accountability are non-negotiable, proprietary systems will remain necessary for validation, integration and trust."

Strong financial returns are driving continued technology investment. NVIDIA's results show that 85% of respondents say their AI budgets will increase and nearly half anticipate growth exceeding 10%. Spending priorities are shifting toward scaling proven solutions – 47% plan to focus on optimising AI workflows and production cycles, compared to 34% the previous year.

Despite momentum, technological barriers remain. Smaller organisations report budget constraints (40%) and insufficient data for training (33%) as top barriers, while larger enterprises cite data-related concerns such as privacy and security (39%) and regulatory issues (37%).

The data indicate that AI technology in healthcare has moved beyond experimentation. With high adoption rates, measurable revenue gains and increasing budget allocations, AI is becoming embedded in clinical workflows, research pipelines and operational systems, positioning the industry for broader technological transformation in the years ahead.